Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.

Journal of clinical pharmacy and therapeutics - 1 Jul 2022

Kaya Michihiro, Nakamura Kazuyo, Sugiyama Kyohei, Kinae Ayumi, Yamaguchi Hiromi, Ukita Hirotoshi, Odagiri Keiichi, Ujiie Chika, Kato Jun, Kageyama Fujito, Nagura Mariko, Matsushita Kumi, Sugiue Kaori, Ishida Hiroki, Endo Shinya, Suzuki Takaya

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: In Japan, ledipasvir/sofosbuvir, elbasvir/grazoprevir and glecaprevir/pibrentasvir are recommended as first-line treatments for patients with untreated hepatitis C virus genotype 1. Although they have demonstrated a high efficacy in clinical trials, there are no direct comparative studies. Clarification of their effectiveness and safety in real-world clinical practice is required....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Drug Therapy, Combination

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 35229326
DOI: 10.1111/jcpt.13624
PMCID: PMC9543670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.PMID 35229326Read ↗

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.Semantic proximity Read ↗

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.Semantic proximity Read ↗

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Semantic proximity Read ↗

Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.Semantic proximity Read ↗

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.Semantic proximity Read ↗

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.Semantic proximity Read ↗

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.Semantic proximity Read ↗

Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.Semantic proximity Read ↗

Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.